• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes

May 19, 2022 By Sean Whooley

Mitsubishi Gas Chemical Company BD Oxycapt syringe
[Image from MGC)
BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes.

MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced biologic pharmaceuticals.

According to a news release, Oxycapt was designed with a multilayer structure applied on silicon-free plastic syringe barrels, providing high breakage resistance, oxygen and vapor barrier, low protein adsorption, very low extractables, high UV barrier and pH stability.

“Since launching Oxycapt, more and more pharmaceutical companies have been interested in applying it to their biologics or regenerative medicines such as gene/cell therapies,” MGC Executive Officer of R&D Ko Kedo said in the release. “As we have looked for a strategic partner to enhance the presence of Oxycapt in the pharmaceutical industry, the partnership with BD will be an ideal solution for MGC. We believe this agreement will make it possible for customers to choose the best syringes for their drugs.”

In the partnership, BD and MGC will explore practical solutions for delivering newer biologic compounds, with both companies also aiming to advance sustainability and reduce carbon footprint throughout the collaboration.

“The biopharmaceutical industry continues to rely on PFS for the effective, reliable and consistent administration of medications,” BD Medical – Pharmaceutical Systems VP of R&D Bruno Baney said. “As our customers continue to grow their drug pipelines we are constantly exploring solutions to deliver newer compounds in robust, stable, and ready-to-administer formats. This agreement will further help us do so – as MGC’s experience in providing technical innovation in materials will serve as a strategic complement to our legacy of supporting the latest innovations in drug delivery for our customers.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: BD, Mitsubishi Gas Chemical Company

IN CASE YOU MISSED IT

  • Lyra Therapeutics appoints new chief medical officer
  • FDA lifts hold on Vertex’s insulin-producing cell therapy for diabetes
  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS